Avihu Tamir's guest appearances

Avihu Tamir

Startup Camel: The startup nation, unveiled

Share Talk LTD

The Cannabis Conversation | Medical Cannabis | CBD | Hemp

The Vox Markets Podcast

Zak Mir

George Frangeskides

Nicholas Lee

Andrew Bell

Paul Haywood

Tony Fabrizi

Michael Masterman

Al Sisto

Nick Pateras

Vadim Alexandre

Galileo Resources

Cathal Friel

Karl Smithson

Andrew Prelea

Clifford Gross

OwlTail

Avihu Tamir CEO of Kanabo #KNB &amp; Nick Pateras, Managing Director of Materia Europe, discuss the positive progress on the Acquisition  HIGHLIGHTS · Agreement reached on majority of commercial terms of the proposed acquisition; · Due diligence on Materia substantively complete; · All share acquisition agreed, valuing Materia at CAN$20MM initially (c.£12million*), with up to an additional CAN$40MM (c.£24million*) payable in new Kanabo shares, upon attainment of post completion performance milestones; · Both the Initial Consideration and the Earn-Out Consideration to be satisfied through the issue of new ordinary shares in the Company;  Update of the Proposed Acquisition Kanabo has completed the majority of the due diligence on Materia and commenced the work on the regulatory documents required to complete the Proposed Transaction. The Parties have also begun planning the integration of the companies once the transaction is completed.    Whilst this announcement contains details of the Term Sheet, the Proposed Transaction is still subject inter alia to the agreement of formal documentation and conditional on, among other things, the receipt of all necessary regulatory consents.  The Consideration The Head of Terms states that the consideration for the Proposed Transaction, which will be subject to the execution of the Share Purchase Agreement and completion, will be satisfied via an initial payment of CAN$20m (c.£12million*) (the "Initial Consideration"). In addition to the Initial Consideration, Materia will be paid an additional consideration of up to CAN$40m (c.£24million*), subject to achieving certain operational and financial milestones (the "Earn-Out Consideration") including, but not limited to:    · Commercial production of two total products in Materia Malta;    · Sales in a new market beyond Germany and Malta;    · Malta production facility reaching a breakeven point.    · Sales of CANS$30million (c. £17.73million*) for the 12-month period to December 31, 2022;    · Sales of CAN$50miliion (c. £29.55million*) for the 12-month period to December 31, 2023; and    Both the Initial Consideration and the Earn-Out Consideration are to be satisfied through the issue of ordinary shares in the Company.  About Materia Materia's medicinal cannabis assets include its Maltese, German, and UK subsidiaries ("Materia Malta", "Materia Germany", and "Materia UK" respectively). Materia Malta operates a European Union Good Manufacturing Practices ("EU GMP") certified facility, through which Materia Malta is able to import cannabis flower from its global supply network of cultivators and process it into EU GMP certified medical cannabis products. The Company anticipates that Materia Malta will be particularly well placed to process any new extracts developed by Kanabo. Materia Germany is a fully operational pharmaceutical wholesaler, with EU GDP and EU GMP certificates, enabling it to import and sell medical cannabis products directly to thousands of German pharmacies. Materia UK sells several leading CBD and wellness brands through Handpicked CBD, which aims to be one of the UK's largest CBD e-commerce marketplaces, and which now features Kanabo's own CBD line, as announced on 22 September 2021.  About Kanabo Group Plc Kanabo Group Plc is an R&amp;D company currently selling a range of wellness CBD Products in the Primary Markets and Medical Cannabis Products. The company's core strategy is to increase revenues from the sale of its Retail CBD Products in the wellness sector and to grow the Kanabo brand through its marketing initiatives.

Avihu Tamir CEO of <a href="https://www.voxmarkets.co.uk/listings/LON/KNB" rel="nofollow" target="_blank">Kanabo #KNB</a> &amp; Nick Pateras, Managing Director of Materia Europe, discuss the positive progress on the Acquisition HIGHLIGHTS · Agreement reached on majority of commercial terms of the proposed acquisition; · Due diligence on Materia substantively complete; · All share acquisition agreed, valuing Materia at CAN$20MM initially (c.£12million*), with up to an additional CAN$40MM (c.£24million*) payable in new Kanabo shares, upon attainment of post completion performance milestones; · Both the Initial Consideration and the Earn-Out Consideration to be satisfied through the issue of new ordinary shares in the Company; Update of the Proposed Acquisition Kanabo has completed the majority of the due diligence on Materia and commenced the work on the regulatory documents required to complete the Proposed Transaction. The Parties have also begun planning the integration of the companies once the transaction is completed. Whilst this announcement contains details of the Term Sheet, the Proposed Transaction is still subject inter alia to the agreement of formal documentation and conditional on, among other things, the receipt of all necessary regulatory consents. The Consideration The Head of Terms states that the consideration for the Proposed Transaction, which will be subject to the execution of the Share Purchase Agreement and completion, will be satisfied via an initial payment of CAN$20m (c.£12million*) (the "Initial Consideration"). In addition to the Initial Consideration, Materia will be paid an additional consideration of up to CAN$40m (c.£24million*), subject to achieving certain operational and financial milestones (the "Earn-Out Consideration") including, but not limited to: · Commercial production of two total products in Materia Malta; · Sales in a new market beyond Germany and Malta; · Malta production facility reaching a breakeven point. · Sales of CANS$30million (c. £17.73million*) for the 12-month period to December 31, 2022; · Sales of CAN$50miliion (c. £29.55million*) for the 12-month period to December 31, 2023; and Both the Initial Consideration and the Earn-Out Consideration are to be satisfied through the issue of ordinary shares in the Company. About Materia Materia's medicinal cannabis assets include its Maltese, German, and UK subsidiaries ("Materia Malta", "Materia Germany", and "Materia UK" respectively). Materia Malta operates a European Union Good Manufacturing Practices ("EU GMP") certified facility, through which Materia Malta is able to import cannabis flower from its global supply network of cultivators and process it into EU GMP certified medical cannabis products. The Company anticipates that Materia Malta will be particularly well placed to process any new extracts developed by Kanabo. Materia Germany is a fully operational pharmaceutical wholesaler, with EU GDP and EU GMP certificates, enabling it to import and sell medical cannabis products directly to thousands of German pharmacies. Materia UK sells several leading CBD and wellness brands through Handpicked CBD, which aims to be one of the UK's largest CBD e-commerce marketplaces, and which now features Kanabo's own CBD line, as announced on 22 September 2021. About Kanabo Group Plc Kanabo Group Plc is an R&amp;D company currently selling a range of wellness CBD Products in the Primary Markets and Medical Cannabis Products. The company's core strategy is to increase revenues from the sale of its Retail CBD Products in the wellness sector and to grow the Kanabo brand through its marketing initiatives.

428: Avihu Tamir of Kanabo & Nick Pateras of Materia discuss the positive progress on the Acquisition

Avihu Tamir of Kanabo Group #KNB &amp; Asaf Sella, CEO Medocann discuss their new partnership for the development of unique new products with exclusive distribution rights into the German and UK medical cannabis markets.  Highlights The partnership agreement between Kanabo and Medocann will focus on the co-development of new and novel strains from flowers and extracts made for specific medical indications through the combination of Kanabo's preclinical data on the effect of cannabis on different illnesses and Medocann's genetics bank, breeding and strain development expertise. The new strains and extracts will be used to launch new co-developed medical cannabis products ("Co-Developed Products").    The agreement includes the exclusive rights to distribute the Co-Developed Products into both the UK and German medical cannabis markets. The agreement stipulates that Medocann and Kanabo will use commercially reasonable efforts to have the Co-Developed Products available for sale in the target markets, based on 1,000kg of cannabis raw material over the first three years of the agreement, conditional on the existence of all required import and export regulatory documents.    The price at which Co-Branded Products will be sold, which will in any event be at least the then-current premium market price, which as of the date of the agreement is estimated at EUR 9.00 (Nine Euros) per gram.  About Kanabo Kanabo Group Plc is an R&amp;D company currently selling a range of THC-Free Retail CBD Products in the Primary Markets and is in the process of developing further Medical Cannabis Products. The company's core strategy is to increase revenues from the sale of its Retail CBD Products in the wellness sector and to grow the Kanabo brand through its marketing initiatives.

Avihu Tamir of <a href="https://www.voxmarkets.co.uk/listings/LON/KNB" rel="nofollow" target="_blank">Kanabo Group #KNB</a> &amp; Asaf Sella, CEO Medocann discuss their new partnership for the development of unique new products with exclusive distribution rights into the German and UK medical cannabis markets. Highlights The partnership agreement between Kanabo and Medocann will focus on the co-development of new and novel strains from flowers and extracts made for specific medical indications through the combination of Kanabo's preclinical data on the effect of cannabis on different illnesses and Medocann's genetics bank, breeding and strain development expertise. The new strains and extracts will be used to launch new co-developed medical cannabis products ("Co-Developed Products"). The agreement includes the exclusive rights to distribute the Co-Developed Products into both the UK and German medical cannabis markets. The agreement stipulates that Medocann and Kanabo will use commercially reasonable efforts to have the Co-Developed Products available for sale in the target markets, based on 1,000kg of cannabis raw material over the first three years of the agreement, conditional on the existence of all required import and export regulatory documents. The price at which Co-Branded Products will be sold, which will in any event be at least the then-current premium market price, which as of the date of the agreement is estimated at EUR 9.00 (Nine Euros) per gram. About Kanabo Kanabo Group Plc is an R&amp;D company currently selling a range of THC-Free Retail CBD Products in the Primary Markets and is in the process of developing further Medical Cannabis Products. The company's core strategy is to increase revenues from the sale of its Retail CBD Products in the wellness sector and to grow the Kanabo brand through its marketing initiatives.

386: Avihu Tamir of Kanabo & Asaf Sella of Medocann discuss their new development & distribution partnership

Deepak Anand

Avihu Tamir CEO of Kanabo Group #KNB &amp; Deepak Anand, CEO of Materia discuss the significance of the commercial production licence for their Malta facility    Kanabo Group Plc (LSE:KNB), a medical cannabis R&amp;D Company that focuses on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, notes the recent announcement published by Materia. Kanabo are delighted that Materia's wholly-owned subsidiary, Materia Malta Operating Ltd. ("Materia Malta"), has received its Licence for the Production of Cannabis for Medicinal and Research Purposes (the "Licence") from the Malta Medicines Authority.    The receipt of the Licence is the final requirement for Materia Malta to begin commercial production and export of medical cannabis for commercial purposes. Materia Malta, which is already EU GMP certified, has an annual throughput capacity of 6,000kg, representing a potential sale value of €36M based on a blended average sales price across several key European markets.    Materia Malta has now begun the process of importing its first batch of raw material for commercial production and will begin fulfillment of its supply commitments across Europe imminently, starting with the initial target markets of Germany, Malta and the UK. The first product has already been successfully registered on the narcotics licence of Materia Deutschland GmbH ahead of its import into and across Germany.  About Kanabo Group Plc Kanabo Group Plc is an R&amp;D company currently selling a range of THC-Free Retail CBD Products in the Primary Markets and is in the process of developing further Medical Cannabis Products. The company's core strategy is to increase revenues from the sale of its Retail CBD Products in the wellness sector and to grow the Kanabo brand through its marketing initiatives.

Avihu Tamir CEO of <a href="https://www.voxmarkets.co.uk/listings/LON/KNB" rel="nofollow" target="_blank">Kanabo Group #KNB</a> &amp; Deepak Anand, CEO of Materia discuss the significance of the commercial production licence for their Malta facility Kanabo Group Plc (LSE:KNB), a medical cannabis R&amp;D Company that focuses on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, notes the recent announcement published by Materia. Kanabo are delighted that Materia's wholly-owned subsidiary, Materia Malta Operating Ltd. ("Materia Malta"), has received its Licence for the Production of Cannabis for Medicinal and Research Purposes (the "Licence") from the Malta Medicines Authority. The receipt of the Licence is the final requirement for Materia Malta to begin commercial production and export of medical cannabis for commercial purposes. Materia Malta, which is already EU GMP certified, has an annual throughput capacity of 6,000kg, representing a potential sale value of €36M based on a blended average sales price across several key European markets. Materia Malta has now begun the process of importing its first batch of raw material for commercial production and will begin fulfillment of its supply commitments across Europe imminently, starting with the initial target markets of Germany, Malta and the UK. The first product has already been successfully registered on the narcotics licence of Materia Deutschland GmbH ahead of its import into and across Germany. About Kanabo Group Plc Kanabo Group Plc is an R&amp;D company currently selling a range of THC-Free Retail CBD Products in the Primary Markets and is in the process of developing further Medical Cannabis Products. The company's core strategy is to increase revenues from the sale of its Retail CBD Products in the wellness sector and to grow the Kanabo brand through its marketing initiatives.

342: Avihu Tamir of Kanabo & Deepak Anand of Materia discuss the significance of commercial production licence

On the Vox Markets Podcast Today: 2nd August 2021   Avihu Tamir CEO of Kanabo #KNB discusses their investment &amp; MoU with Hellenic Dynamics, the acquisition of a European Medical Cannabis Producer &amp; Distributor plus their first Medical Cannabis Product in the UK   Christian Taylor-Wilkinson, CEO of Altona Rare Earths #ANR covers the highlights from their Final Results &amp; maps out what's to come in the next year. (Interview starts at 15 minutes 54 seconds)   Alan Green CEO of Brand Communications talks about: Itaconix #ITX Airtel Africa #AAF &amp; Royal Dutch Shell #RDSB (Interview starts at 24 minutes 35 seconds)   Plus the Top 5 Most Followed Companies &amp; the Top 5 Most read RNS’s on Vox Markets in the last 24 hours.   Vox Markets is revolutionising the way companies engage with shareholders and the stock market at large. By aggregating IR and digital content onto one secure and compliant platform, Vox Markets has established itself as the go-to resource for the investment community.   #VoxMarkets #StockMarket #LivePrices #StockMarketNews #Money #Investing #Investments #Finance #Business #Podcast  https://www.voxmarkets.co.uk/

On the Vox Markets Podcast Today: 2nd August 2021 Avihu Tamir CEO of Kanabo #KNB discusses their investment &amp; MoU with Hellenic Dynamics, the acquisition of a European Medical Cannabis Producer &amp; Distributor plus their first Medical Cannabis Product in the UK Christian Taylor-Wilkinson, CEO of Altona Rare Earths #ANR covers the highlights from their Final Results &amp; maps out what's to come in the next year. (Interview starts at 15 minutes 54 seconds) Alan Green CEO of Brand Communications talks about: Itaconix #ITX Airtel Africa #AAF &amp; Royal Dutch Shell #RDSB (Interview starts at 24 minutes 35 seconds) Plus the Top 5 Most Followed Companies &amp; the Top 5 Most read RNS’s on Vox Markets in the last 24 hours. Vox Markets is revolutionising the way companies engage with shareholders and the stock market at large. By aggregating IR and digital content onto one secure and compliant platform, Vox Markets has established itself as the go-to resource for the investment community. #VoxMarkets #StockMarket #LivePrices #StockMarketNews #Money #Investing #Investments #Finance #Business #Podcast <a href="https://www.voxmarkets.co.uk/" rel="nofollow" target="_blank">https://www.voxmarkets.co.uk/</a>

277: Avihu Tamir CEO of Kanabo, Christian Taylor-Wilkinson CEO of Altona Rare Earths & Alan Green on 3 Stocks

Avihu Tamir, CEO Kanabo (KNB) and Nick Pateras, Managing Director (Europe) of Materia discuss the proposed acquisition of Materia. They highlight the opportunities in the medical cannabis space, especially in Germany, as well as the way that Materia specialises in innovation and distribution of products. Tamir looks forward to the deal being essentially a merger of the two companies, and enhancing value for Kanabo.

271: Vox Markets Podcast: Avihu Tamir, CEO Kanabo (KNB) and Nick Pateras, Managing Director (Europe) of Materia

Kanabo Group Plc (formerly Spinnaker Opportunities Plc) announces that admission of the Company's ordinary shares to trading on London Stock Exchange ("Admission") will take place and dealings will commence at 8.00 a.m. today under the ticker KNB (ISIN: GB00BYQCS703).   Avihu Tamir, CEO of Kanabo Group Plc, says:    "We are proud and happy to be listed on London Stock Exchange. I would like to thank Spinnaker Opportunities and the whole transaction team for helping us to reach this goal and to thank new and existing shareholders who have invested in our pioneering endeavour.    We share the enthusiasm shown by the investment community in the UK for this important day. The reaction we have seen since we published our prospectus two weeks ago has been overwhelming. With the support of the FCA and London Stock Exchange, the medical cannabis industry is set to take off in the UK and in Europe, similar to what's happened in North America in recent times. This is just the beginning".  https://www.share-talk.com/avihu-tamir-ceo-of-kanabo-group-plc-knb-l-first-day-of-dealings-interview/

Kanabo Group Plc (formerly Spinnaker Opportunities Plc) announces that admission of the Company's ordinary shares to trading on London Stock Exchange ("Admission") will take place and dealings will commence at 8.00 a.m. today under the ticker KNB (ISIN: GB00BYQCS703). Avihu Tamir, CEO of Kanabo Group Plc, says: "We are proud and happy to be listed on London Stock Exchange. I would like to thank Spinnaker Opportunities and the whole transaction team for helping us to reach this goal and to thank new and existing shareholders who have invested in our pioneering endeavour. We share the enthusiasm shown by the investment community in the UK for this important day. The reaction we have seen since we published our prospectus two weeks ago has been overwhelming. With the support of the FCA and London Stock Exchange, the medical cannabis industry is set to take off in the UK and in Europe, similar to what's happened in North America in recent times. This is just the beginning". <a href="https://www.share-talk.com/avihu-tamir-ceo-of-kanabo-group-plc-knb-l-first-day-of-dealings-interview/" rel="nofollow" target="_blank">https://www.share-talk.com/avihu-tamir-ceo-of-kanabo-group-plc-knb-l-first-day-of-dealings-interview/</a>

Avihu Tamir,  CEO of Kanabo Group Plc (KNB.L) First Day of Dealings, Interview 

In this episode, we speak to Avihu Tamir, cannabis entrepreneur with over five years of hands-on experience in multiple Israeli medical cannabis ventures. Avihu is the founder and CEO of Kanabo Research, who are dedicated to unlocking Cannabis' secrets through science. Kanabo Research focus on developing medically-validated cannabis IP, primarily via extractions and delivery systems. Its mission is to meet the growing demand for non-smoking alternatives and license its IP to global partners.Together, we dive into the Cannabis market in Israel, discovering how this unique market differs from its European counterparts, and finding out what research is currently taking place.  Show notes: https://www.canverse.global/shownotes/episode-23-the-cannabis-industry-in-israel-with-avihu-tamir-ceo-of-kanabo-research

In this episode, we speak to Avihu Tamir, cannabis entrepreneur with over five years of hands-on experience in multiple Israeli medical cannabis ventures. Avihu is the founder and CEO of Kanabo Research, who are dedicated to unlocking Cannabis' secrets through science. Kanabo Research focus on developing medically-validated cannabis IP, primarily via extractions and delivery systems. Its mission is to meet the growing demand for non-smoking alternatives and license its IP to global partners.Together, we dive into the Cannabis market in Israel, discovering how this unique market differs from its European counterparts, and finding out what research is currently taking place.  Show notes: <a href="https://www.canverse.global/shownotes/episode-23-the-cannabis-industry-in-israel-with-avihu-tamir-ceo-of-kanabo-research" rel="nofollow" target="_blank">https://www.canverse.global/shownotes/episode-23-the-cannabis-industry-in-israel-with-avihu-tamir-ceo-of-kanabo-research</a>

EPISODE #23 Cannabis in Israel with Avihu Tamir, CEO of Kanabo Research

Kanabo Research is a biotech company pioneering cutting edge solutions in the medical cannabis industry. Kanabo brings together decades of experience in some of the most important fields revolutionizing the medical world; including extraction technologies, medical devices, delivery systems and more. Kanabo’s mission is to provide turnkey solutions to licensed companies looking to expand their product offering, generate new revenue streams and learn the most advanced technologies developed in Israel’s centers of R&amp;D excellence.